ChemoCentryx Regains Crohn’s Candidate Vercirnon From GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK will continue development of a rheumatoid arthritis candidate optioned from ChemoCentryx in 2011 and is expected to decide before year’s end on whether to license a Phase II candidate for renal vasculitis from the California biotech.